By Kailyn Rhone
NeuroPace expects to report a rise in fourth quarter and full-year sales.
The Mountain View, Calif.-based medical device company gave preliminary fourth quarter results on Wednesday, and said it forecasts sales of $21 million to $21.5 million, an increase of 17% to 19%.
For the full fiscal year, NeuroPace said it now expects sales of $79.4 million to $79.9 million, up 21% to 22%. It previously guided for full-year sales to be $73 million to $77 million.
Cash and short-term investments as of Dec. 31 are expected to be $52.8 million.
NeuroPace said its Nautilus pivotal trial is on track to complete the required one year follow-up of subjects in March. It also anticipates the data lock and subsequent trial data analysis commencing in the second quarter.
Write to Kailyn Rhone at kailyn.rhone@wsj.com
(END) Dow Jones Newswires
January 08, 2025 17:02 ET (22:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。